Clinical Study Of Albumin-bound Paclitaxel In The Treatment Of Recurrent Ovarian Cancer

Objective: To observe the clinical efficacy and safety of albumin-bound paclitaxel combined with platinum or ifosfamide in the treatment of recurrent ovarian cancer.Methods: 46 cases of recurrent ovarian cancer patients received different formulations of paclitaxel combined with platinum or ifosfamide were analyzed retrospectively.26 platinum-sensitive patients with recurrent ovarian cancer were treated with either albumin-bound paclitaxel or solvent-based paclitaxel combined with carboplatin.20 platinum-resistant patients with recurrent ovarian cancer were treated with albumin-bound paclitaxel or solvent-based paclitaxel combined with ifosfamide,every 21 days a cycle,until complete remission and consolidation for another two courses or disease progression or intolerable adverse reactions.The clinical effects,side effects and prognosis of four groups were compared.Results: In platinum-sensitive patients,the complete remission rate was 60% in albumin-bound paclitaxel-treated patients and 18.8% in solvent-based paclitaxel-treated patients(P<0.05).The objective response rates were 90% and 75%,respectively.In platinum-resistant patients,the complete remission rate was 16.7% in albumin-bound paclitaxel group and 0% in solvent-based paclitaxel group(P<0.05).The objective response rates were 66.7% and 57.1% respectively.In platinum-sensitive relapsed patients,the median progression-free survival(PFS)of albumin-bound paclitaxel and solvent-paclitaxel groups were 10.25 and 7.5 months respectively(P<0.05).In platinum-resistant relapsed patients,the median PFS of albumin-bound paclitaxel and solvent-based paclitaxel groups were 7.8 and 5.6 months respectively(P<0.05).The main adverse effects of the four groups are bone marrow suppression and gastrointestinal reaction.In platinum-sensitive or platinum-resistant patients,there were no significant differences in the incidence of Ⅲ-Ⅳgrade adverse reactions between albumin-bound paclitaxel and solvent-based paclitaxel groups(P>0.05).Conclusion: Compared with solvent-based paclitaxel,albumin-bound paclitaxel based chemotherapy regime has a higher complete remission rate,prolonger PFS and no more toxicity in platinum-sensitive or platinum-resistant recurrent ovarian cancer patients.